title: Do we need authorized orphan drugs when compounded medications are available?
abstract: OBJECTIVE
  Orphan drugs are used to diagnose, prevent or treat a rare disease. This Commentary aims to present a number of case studies questioning the need for designating compounded medications with a long history of effective use, which is well-supported by published clinical evidence.
  
  
  CONCLUSIONS
  Prior to the market introduction of orphan drugs, medication compounding was done in our hospital pharmacy for several rare diseases. Examples include amifampridine for the treatment of Lambert-Eaton myasthenic syndrome (Firdapse(®)), ibuprofen for the treatment of neonatal patent ductus arteriosus (Pedea(®)) and zinc acetate for the treatment of Wilson's disease (Wilzin(®)). Several 'non-orphan' pharmaceutical products, used off-label for the treatment of rare diseases, that became orphan medicinal products include Hydrea(®) for the treatment of sickle-cell syndrome (Siklos(®)) and Viagra(®) for the treatment of pulmonary arterial hypertension (Revatio(®)).
  
  
  CONCLUSIONS
  In our opinion, as indicated by our examples, a better balance should be struck between the development of orphan drugs along the recently established regulatory pathways and the pragmatic use of pharmacy-compounded products and evidence-based off-label use of already available commercial products. Societal needs would be best met by focusing orphan drug development on rare diseases for which there is a high unmet medical need.
authors.affiliation: Hospital Pharmacy, University Hospitals Leuven, Leuven, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Dooms
authors.forename: H
authors.initials: H
authors.lastname: Pincé
authors.forename: S
authors.initials: S
authors.lastname: Simoens
mesh_terms: D004339:Drug Compounding / Q000379:methods*; D015195:Drug Design; D005062:European Union; D006301:Health Services Needs and Demand; D006801:Humans; D056687:Off-Label Use; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence / Q000379:methods*; D010593:Pharmaceutical Services / Q000458:organization & administration; D035583:Rare Diseases / Q000188:drug therapy*